RxDoctor Payments Data

Ravi Chander, MD

Neurology · Chattanooga, TNNPI 1578511598

Payments from drug & device makers

$4,421in general payments, 2019–2025

Across 332 payments — averaging $13.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$778
  • Biohaven Pharmaceutical Holding Company Ltd.$685
  • AbbVie$426
  • Biogen$235
  • EMD Serono, Inc.$232
  • Sunovion Pharmaceuticals Inc.$223
  • plus $2K from 26 others

What the payments were for

  • Speaking & faculty fees$651%
  • Food & beverage$4,16594%
  • Education$1914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,421 in reported general payments places this provider in the 50th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$14,907
Medicare patients
68
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate28$36,343
Emgality PenGalcanezumab-Gnlm50$34,552
Nurtec OdtRimegepant Sulfate15$19,695
Lacosamide100$14,824
Aimovig AutoinjectorErenumab-Aooe20$14,636
DepakoteDivalproex Sodium12$10,228
Carbidopa-Levodopa ErCarbidopa/Levodopa120$8,229
Levetiracetam177$8,141
Memantine Hcl122$3,076
Carbamazepine ErCarbamazepine12$1,577
Donepezil Hcl139$1,338
Zonisamide47$1,195
Carbamazepine32$1,172
Propranolol Hcl ErPropranolol Hcl15$897
Lamotrigine53$873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$223$36,34328 claims
PfizerNurtec Odt$219$19,69515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 361 neurology providers in Tennessee.

Other neurology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →